Irinotecan Glenmark

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Glenmark, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous administration. It is indicated for the treatment of metastatic colorectal cancer in adult patients, where it acts to disrupt tumor DNA replication and is administered under the supervision of qualified oncology specialists.

GNH USA supplies Irinotecan Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this essential antineoplastic agent for cancer care programs. The company adheres to stringent quality standards and supports global distribution networks to ensure timely delivery.

Irinotecan Glenmark, a topoisomerase I inhibitor used in oncology, is indicated for the following conditions:

Metastatic colorectal cancer: Improves disease control and overall survival when used in combination chemotherapy regimens.

Irinotecan Glenmark may cause a range of adverse reactions during treatment.

Common Side Effects: - Neutropenia: Reduced white blood cell count increasing infection risk. - Diarrhea: Often severe, may require antidiarrheal therapy. - Nausea and vomiting: Common gastrointestinal symptoms. - Alopecia: Hair loss during therapy. - Fatigue: Generalized tiredness and weakness. - Anemia: Decreased red blood cell count causing fatigue.

Serious or Rare Side Effects: - Febrile neutropenia: Fever with low neutrophils, a medical emergency. - Severe colitis: Life‑threatening inflammation of the colon. - Cholinergic syndrome: Abdominal cramps, sweating, and bradycardia. - Hypersensitivity reactions: Rash, bronchospasm, or anaphylaxis. - Hepatic toxicity: Elevated liver enzymes or jaundice. - Electrolyte disturbances: Particularly hypokalemia.

Before initiating Irinotecan Glenmark, clinicians should assess patient suitability and monitor for potential complications.

Monitor blood counts: Perform regular CBC to detect neutropenia. Assess liver function: Check hepatic enzymes prior to each cycle. Hydration status: Ensure adequate fluid intake to mitigate severe diarrhea. Genetic testing: Consider UGT1A1 genotype to predict toxicity risk. Avoid concurrent strong CYP3A4 inhibitors: May increase drug exposure. Store at ambient temperature: Keep in original container, protect from moisture and light.

Irinotecan Glenmark can interact with several medicines; awareness of interaction severity helps guide safe use.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: May raise irinotecan plasma levels. - UGT1A1 inhibitors: Increase risk of severe toxicity. - Live vaccines: Contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: May worsen cholinergic syndrome. - Antiemetics such as ondansetron: Can affect metabolism. - Warfarin: Monitor INR for altered anticoagulation. - Proton pump inhibitors: May influence drug absorption. - Herbal supplements (e.g., St. John’s wort): Potential enzyme induction.